Edjah K Nduom

List of Publications by Year
in descending order

60	1,722	430442	329751
papers	citations	18 h-index	37 g-index

64	64	64	3421
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology, 2016, 18, 195-205.	0.6	463
2	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. Neuro-Oncology, 2015, 17, vii9-vii14.	0.6	275
3	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology, 2016, 18, 639-648.	0.6	161
4	Effect of miR-142-3p on the M2 Macrophage and Therapeutic Efficacy Against Murine Glioblastoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	112
5	Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms. Journal of Neurosurgery, 2013, 119, 427-433.	0.9	102
6	Acute Lung Injury Is an Independent Risk Factor for Brain Hypoxia After Severe Traumatic Brain Injury. Neurosurgery, 2010, 67, 338-344.	0.6	57
7	The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma. Fluids and Barriers of the CNS, 2018, 15, 2.	2.4	55
8	Glioblastoma Cancer Stem-Like Cells. Cancer Journal (Sudbury, Mass), 2012, 18, 100-106.	1.0	51
9	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight, 2019, 4, .	2.3	40
10	Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. BMC Cancer, 2018, 18, 239.	1.1	38
11	Biomarkers for immunotherapy for treatment of glioblastoma. , 2020, 8, e000348.		33
12	Canine Model of Convection-Enhanced Delivery of Cetuximab-Conjugated Iron-Oxide Nanoparticles Monitored With Magnetic Resonance Imaging. Neurosurgery, 2012, 59, 107-113.	0.6	31
13	Nanotechnology Applications for Glioblastoma. Neurosurgery Clinics of North America, 2012, 23, 439-449.	0.8	29
14	Distinct phenotypic states and spatial distribution of CD8+ TÂcell clonotypes in human brain metastases. Cell Reports Medicine, 2022, 3, 100620.	3.3	29
15	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade. Neurosurgery, 2019, 84, 945-953.	0.6	24
16	GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models. Scientific Reports, 2020, 10, 11003.	1.6	24
17	Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro-Oncology, 2016, 19, now198.	0.6	23
18	Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery, 2019, 85, 280-289.	0.6	22

#	Article	IF	Citations
19	Current Options and Future Directions in Immune Therapy for Glioblastoma. Frontiers in Oncology, 2018, 8, 578.	1.3	21
20	A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma. Neurosurgery, 2021, 89, 712-719.	0.6	19
21	Imaging detection of endolymphatic sac tumorâ€“associated hydrops. Journal of Neurosurgery, 2013, 119, 406-411.	0.9	15
22	Letter: A Call to Action: Increasing Black Representation in Neurological Surgery. Neurosurgery, 2021, 88, E469-E473.	0.6	15
23	Induction of Immune Response against Metastatic Tumors via Vaccination of Mannanâ€BAM, TLR Ligands, and Antiâ€CD40 Antibody (MBTA). Advanced Therapeutics, 2020, 3, 2000044.	1.6	11
24	Brain Tumor Discussions on Twitter (#BTSM): Social Network Analysis. Journal of Medical Internet Research, 2020, 22, e22005.	2.1	11
25	Young Neurosurgeons Committee of the American Association of Neurological Surgeons: Training Ground for Future Leaders in Organized Neurosurgery in the United States of America. World Neurosurgery, 2019, 123, 59-63.	0.7	9
26	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro-Oncology, 2022, 24, 1219-1229.	0.6	9
27	Comparison of pulsed versus continuous convective flow for central nervous system tissue perfusion. Journal of Neurosurgery, 2012, 117, 1150-1154.	0.9	8
28	Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review. Journal of Neuro-Oncology, 2022, 157, 187-195.	1.4	6
29	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery, 2021, 89, 129-132.	0.6	5
30	SNO 25th anniversary history series: Providing a global platform for communication and exchange in neuro-oncology. Neuro-Oncology, 2020, 22, 1551-1552.	0.6	4
31	miR-138 exerts anti-glioma efficacy by targeting immune checkpoints. , 2013, 1, .		3
32	Neuroendoscopic Resection of Intraventricular Tumors and Cysts through a Working Channel with a Variable Aspiration Tissue Resector: A Feasibility and Safety Study. Minimally Invasive Surgery, 2013, 2013, 1-8.	0.1	3
33	IMPS-28PD-L1 EXPRESSION AND PROGNOSTIC IMPACT IN GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v119.2-v119.	0.6	3
34	Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section. Journal of Neuro-Oncology, 2020, 149, 161-170.	1.4	3
35	Blood-brain barrier. Response. Journal of Neurosurgery, 2014, 120, 291.	0.9	2
36	Transnasal approaches to the sellar and parasellar region: Open and endoscopic. Operative Techniques in Otolaryngology - Head and Neck Surgery, 2013, 24, 208-212.	0.1	1

#	Article	IF	Citations
37	TMOD-05. GLIOMA-261 LUCIFERASE-EXPRESSING CELL LINE STIMULATES AN IMMUNOGENIC RESPONSE SIGNATURE IN AN IMMUNOCOMPETENT MURINE MODEL. Neuro-Oncology, 2018, 20, vi269-vi269.	0.6	1
38	Letter: A Proposal for Medical Student Inclusion on the Editorial Boards of Neurosurgical Journals. Neurosurgery Open, 2021, 2, .	0.7	1
39	Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post Immunotherapy. Frontiers in Oncology, 2020, 10, 601452.	1.3	1
40	Abstract 4291: An optimized therapeutic nanoparticle delivery platform of miRNA in preclinical murine models of malignancy. , 2015, , .		1
41	IT-22 * TARGETING THE IMMUNE CHECKPOINT NETWORK WITH miR-138 EXERTS THERAPEUTIC EFFICACY IN MURINE MODELS OF GLIOMA. Neuro-Oncology, 2014, 16, v114-v114.	0.6	0
42	IMPS-41IMMUNE MODULATORY NANOPARTICLE THERAPEUTICS. Neuro-Oncology, 2015, 17, v122.1-v122.	0.6	0
43	ACTR-85. THE EFFECT OF REGADENOSON ON TEMOZOLOMIDE NEUROPHARMACOKINETICS IN GLIOBLASTOMA PATIENTS MEASURED BY INTRACEREBRAL MICRODIALYSIS. Neuro-Oncology, 2017, 19, vi19-vi19.	0.6	0
44	IMMU-02. VALIDATION OF PD-L1 EXPRESSION IN HIGH GRADE GLIOMAS AS AN INDEPENDENT NEGATIVE PROGNOSTIC MARKER. Neuro-Oncology, 2017, 19, vi112-vi112.	0.6	0
45	CBIO-11. UPREGULATION OF THE TGF-Î² PATHWAY DRIVES TRANSFORMATION OF GLIOBLASTOMA INTO GLIOSARCOMA AND OSTEOSARCOMA. Neuro-Oncology, 2017, 19, vi35-vi35.	0.6	0
46	IMMU-68. SINGLE-CELL PROTEOMIC ANALYSIS OF IMMUNE CELL RESPONSE TO CHECKPOINT BLOCKADE USING 30-PARAMETER FLOW CYTOMETRY. Neuro-Oncology, 2018, 20, vi137-vi137.	0.6	0
47	RARE-26. MUTATIONS IN MAPK PATHWAY GENES ARE CHARACTERISTIC AND CONFIRMATORY OF MULTINODULAR AND VACUOLATING NEURONAL TUMOR OF THE CEREBRUM. Neuro-Oncology, 2018, 20, vi241-vi241.	0.6	0
48	The Luciferase-Expressing Glioma-261 Murine Models Elicit an Immune-Mediated Antitumor Response. Neurosurgery, 2019, 66, .	0.6	0
49	TMOD-32. GL261 LUCIFERASE-EXPRESSING CELLS ELICIT AN ANTI-TUMOR IMMUNE RESPONSE: AN EVALUATION OF MURINE GLIOMA MODELS. Neuro-Oncology, 2019, 21, vi269-vi270.	0.6	0
50	EPID-30. A TWITTER-BASED NETWORK ANALYSIS OF BRAIN TUMOR SOCIAL MEDIA (#BTSM). Neuro-Oncology, 2019, 21, vi81-vi81.	0.6	0
51	TMIC-28. LONG NON-CODING RNA EXPRESSION DIFFERS BETWEEN GLIOBLASTOMA PATIENT IMMUNE CELLS AND HEALTHY VOLUNTEERS. Neuro-Oncology, 2019, 21, vi253-vi253.	0.6	0
52	Resection of Myxopapillary Ependymoma of the Filum Terminale: 2-Dimensional Operative Video. Operative Neurosurgery, 2020, 18, E40-E40.	0.4	0
53	Metastases to the Central Nervous System: A Comprehensive Guide on Current Management and Future Directions. Neurosurgery Clinics of North America, 2020, 31, xiii-xiv.	0.8	0
54	Metastases to the Central Nervous System. Neurosurgery Clinics of North America, 2020, 31, i.	0.8	0

#	Article	IF	Citations
55	Why would a Black man volunteer for a government-funded science experiment?. EClinicalMedicine, 2021, 33, 100788.	3.2	0
56	Abstract 3335: Identification of candidate proteins for the targeted imaging and therapy of glioma stem cells: Effect of antibody-conjugated magnetic nanoparticles and proteasomal inhibitor bortezomib on GBM-derived neurospheres and glioma stem cell marker CD133. , 2010, , .		0
57	Treatment of Brainstem Hemangioblastomas. , 2012, , 231-238.		0
58	A first-in-human phase I single-agent dose-escalation, food effect and dose expansion study of oral ONC206 in recurrent and rare primary central nervous system neoplasms.. Journal of Clinical Oncology, 2020, 38, TPS2576-TPS2576.	0.8	0
59	SURG-21. A CROWDSOURCED CONSENSUS ON SUPRATOTAL RESECTION VERSUS GROSS TOTAL RESECTION FOR ANATOMICALLY DISTINCT PRIMARY GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii207-ii208.	0.6	0
60	Letter to the Editor. Diversity-related studies in neurosurgery: concerns and suggestions. Journal of Neurosurgery: Spine, 2022, 37, 781-782.	0.9	0